Jump to content

ATC code

From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Daevatgl (talk | contribs) at 16:59, 26 June 2004. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

ATC code (Anatomic Therapeutical Chemical) is a drug classification system. In the ATC system drugs are divided into different groups and sub-groups, according on which part of the body the act, and also on the basis of their therapeutical, pharmaceutical and chemical properties. There are 5 levels in the ATC classification system. In the first level, the drugs are divided in 14 main groups. Each of these 14 groups is furthermore divided into 4 sub-groups. The second and the third subgroup are pharmaceutical or therapeutical sub-groups. The fourth sub-group indicates the chemical, therapeutical or pharmacological group the substance belongs to. The last sub-group is the individual substance

For example, ciprofloxacin's ATC code would be J01MA02

  • J Anti-infectives for systemic use
    • J01 Antibacterials for systemic use
      • J01M Quinolone antibacterials
        • J01MA Fluoroquinolones
          • J01MA02 Ciprofloxacin

List of ATC groups

A Alimentary tract and metabolism

A01 Stomatological preparations
A01A Stomatological preparations
A01AA Caries prophylactic agents
A01AB Anti-infectives and antiseptics for local oral treatment
A01AC Corticosteroids for local oral treatment
A01AD Other agents for local oral treatment
A02 Drugs for acid related disorders
A02A Antacids
A02AA Magnesium compounds
A02AB Aluminium compounds
A02AC Calcium compounds
A02AD Combinations and complexes of aluminium, calcium and magnesium compounds
A02AF Antacids with antiflatulents
A02AG Antacids with antispasmodics
A02AH Antacids with sodium bicarbonate
A02AX Antacids, other combinations
A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BA H2-receptor antagonists